Hugel Aesthetics Expands Its Footprint in the U.S. with Medical and Consumer Investments

Hugel Aesthetics Expands Its U.S. Presence

Hugel Aesthetics, a renowned player in the global aesthetics market, has unveiled its ambitious plan to enhance its operations in the United States. This strategic expansion marks a pivotal moment in the company’s growth strategy, reflecting its commitment to transforming the aesthetic treatment landscape. The centerpiece of this initiative is the launch of a dedicated sales force and medical affairs team focused on the U.S. market. This direct engagement aims to bolster the adoption of Letybo, Hugel’s flagship neurotoxin product, which has dominated the South Korean market as the best-selling neurotoxin for a decade.

Key Initiatives and Launches

As part of this expansion, Hugel Aesthetics will invest in a comprehensive direct sales organization and implement a field-based medical affairs team. This approach is expected to enhance customer support significantly and provide aesthetic practices with immediate access to experienced representatives who can facilitate the seamless integration of Letybo into various treatment protocols. Furthermore, the company has committed to a consumer-focused K-TOX campaign aimed at elevating brand awareness and reinforcing Letybo’s reputation among both consumers and aesthetic providers.

Letybo: Trusted by Professionals Worldwide

Letybo, which received FDA approval in February 2024 and was launched in March 2025 through a partnership with BENEV® Company Inc., is already making strides. Over 9,000 practices have begun incorporating the neurotoxin into their treatment offerings, and Hugel is leveraging a hybrid distribution strategy that combines partner-led initiatives with direct sales efforts to ensure continued success in the U.S. aesthetics market. Carrie Strom, President and Global CEO of Hugel, emphasized the product's proven safety and effectiveness, noting that over 44 million treatments have been performed in more than 70 countries with the highest standards of clinical support backing these procedures.

Commitment to Education and Innovation

Hugel is dedicated to providing educational resources for clinicians, facilitating peer-to-peer knowledge sharing and collaboration through medical congress support and ongoing clinical research. Dr. Michael H. Gold, a renowned dermatologist and U.S. Letybo investigator, praised Hugel's commitment to advancing industry standards, noting the importance of comprehensive education and scientific exchange in the evolving field of aesthetic treatments. He expressed that the collaboration with Hugel enables healthcare providers to stay at the forefront of innovations, directly benefiting patient care and business success.

The K-TOX Campaign: Harnessing Korean Aesthetic Leadership

The K-TOX initiative, inspired by South Korea’s reputation as a leader in aesthetic innovation, aims to create a bridge between consumers and practitioners, highlighting the effectiveness and credibility of Letybo. The campaign showcases Letybo’s status as the leading neurotoxin product in South Korea for 10 consecutive years, amidst a competitive landscape of more than 15 neuromodulator options. The campaign not only seeks to amplify Letybo’s visibility but also reinforces Hugel's overarching commitment to delivering trusted and clinically proven aesthetic solutions.

Looking Ahead: A Focus on Strategic Accounts

Throughout 2026, Hugel will place substantial focus on strategic customer accounts in the U.S., while BENEV will continue to address other accounts across the market. This refined approach positions Hugel to optimize its resources, ensuring that both medical professionals and patients receive the highest quality of service and products.

For further information on Hugel's offerings and the latest updates, visit hugel-aesthetics.com.

Important Safety Information

While Letybo is heralded for its efficacy, it is important to note potential serious side effects. Patients should be aware of risks such as difficulty in swallowing, speaking, or breathing due to muscle weakening, as well as possible broader toxin effects. Individuals with specific medical conditions or allergies should consult healthcare providers prior to treatment. The most common side effect reported by users has been headaches, underscoring the importance of thorough discussions with licensed healthcare professionals prior to beginning treatment.